Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Ovarian Research
Published in: Journal of Ovarian Research 1/2016

Open Access 01-12-2016 | Research

Circulating anti-mullerian hormone as predictor of ovarian response to clomiphene citrate in women with polycystic ovary syndrome

Authors: Wenyan Xi, Yongkang Yang, Hui Mao, Xiuhua Zhao, Ming Liu, Shengyu Fu

Published in: Journal of Ovarian Research | Issue 1/2016

Login to get access

Abstract

Background

To investigate the impact of high circulating AMH on the outcome of CC ovulation induction in women with PCOS.

Methods

This prospective cohort observational study included 81 anovulatory women with PCOS who underwent 213 cycles of CC ovarian stimulation. Serum AMH concentrations were measured on cycle day 3 before the commencement of CC in the first cycle, which were compared between responders and CC-resistant anovulation (CRA). Logistic regression analysis was applied to study the value of serum AMH for the prediction of ovarian responsiveness to CC stimulation. The receiver-operating characteristic (ROC) curve was used to evaluate the prognostic value of circulating AMH.

Main outcome measures

Serum AMH levels.

Results

Women who ovulated after CC therapy had a significantly lower AMH compared with the CRA (5.34 ± 1.97 vs.7.81 ± 3.49, P < 0.001). There was a significant gradient increase of serum AMH levels with the increasing dose of CC required to achieve ovulation (P < 0.05). In multivariate logistic regression analysis, AMH was an independent predictor of ovulation induction by CC in PCOS patients. ROC curve analysis showed AMH to be a useful predictor of ovulation induction by CC in PCOS patients, having 92 % specificity and 65 % sensitivity when the threshold AMH concentration was 7.77 ng/ml.

Conclusion

Serum AMH may be clinically useful to predict which PCOS women are more likely to respond to CC treatment and thus to direct the selection of protocols of ovulation induction.
Literature
1.
2.
Webber LJ, Stubbs S, Stark J, Trew GH, Margara R, Hardy K, et al. Formation and early development of follicles in the polycystic ovary. Lancet. 2003;27:1017–21.CrossRef
3.
Jonard S, Dewailly D. The follicular excess in polycystic ovaries due to intra-ovarian hyperandrogenism, may be the main culprit for the follicular arrest. Hum Reprzod Update. 2004;10:107–17.CrossRef
4.
Pigny P, Merlen E, Robert Y, Cortet-Rudelli C, Decanter C, Jonard S, et al. Elevated serum level of anti-Mullerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest. J Clin Endocrinol Metab. 2003;88:5957–62.CrossRefPubMed
5.
Pigny P, Jonard S, Robert Y, Dewailly D. Serum anti-Mullerian hormone as a surrogate for antral follicle count for definition of the polycystic ovary syndrome. J Clin Endocrinol Metab. 2006;91:941–5.CrossRefPubMed
6.
Cook CL, Siow Y, Brenner AG, Fallat ME. Relationship between serum Mullerian-inhibiting substance and other reproductive hormones in untreated women with polycystic ovary syndrome and normal women. Fertil Steril. 2002;77:141–6.CrossRefPubMed
7.
Laven JS, Mulders AG, Visser JA, Themmen AP, Jong FH, Fauser BC. Anti-Mullerian hormone serum concentrations in normovulatory and anovulatory women of reproductive age. J Clin Endocrinol Metab. 2004;89:318–23.CrossRefPubMed
8.
Mitwally MF, Casper RF. Use of an aromatase inhibitor for induction of ovulation in patients with an inadequate response to clomiphene citrate. Fertil Steril. 2001;75:305–9.CrossRefPubMed
9.
Broer SL, Mol BW, Hendriks D, Broekmans FJ. The role of anti-Mullerian hormone in prediction of outcome after IVF: comparison with the antral follicle count. Fertil Steril. 2009;91:705–14.CrossRefPubMed
10.
Elgindy EA, El-Haieg DO, El-Sebaey A. Anti-Mullerian hormone: correlation of early follicular, ovulatory and midluteal levels with ovarian response and cycle outcome in intracytoplasmic sperm injection patients. Fertil Steril. 2008;89:1670–6.CrossRefPubMed
11.
Lekamge DN, Barry M, Kolo M, Lane M, Gilchrist RB, Tremellen KP. Anti-Mullerian hormone as a predictor of IVF outcome. Reprod Biomed Online. 2007;14:602–10.CrossRefPubMed
12.
Xi W, Gong F, Lu G. Correlation of serum Anti-Mullerian hormone concentrations on day 3 of the in vitro fertilization stimulation cycle with assisted reproduction outcome in polycystic ovary syndrome patients. J Assist Reprod Genet. 2012;29:397–402.PubMedCentralCrossRefPubMed
13.
Amer SA, Mahran A, Abdelmaged A, El-Adawy AR, Eissa MK, Shaw RW. The influence of circulating anti-Müllerian hormone on ovarian responsiveness to ovulation induction with gonadotrophins in women with polycystic ovarian syndrome: a pilot study. Reprod Biol Endocrinol. 2013;11:115.PubMedCentralCrossRefPubMed
14.
Rotterdam ESHRE/ASRM–Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term healthy risks related to polycystic ovary syndrome. Fertil Steril. 2004;81:19–25.
15.
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–9.CrossRefPubMed
16.
Balen AH, Laven JS, Tan SL, Dewailly D. Ultrasound assessment of the polycystic ovary: international consensus definitions. Hum Reprod Update. 2003;9:505–14.CrossRefPubMed
17.
La Marca A, Sighinolfi G, Radi D, Argento C, Baraldi E, Artenisio AC, et al. Anti-Mu llerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). Hum Reprod Update. 2010;16:113–30.CrossRefPubMed
18.
Nakhuda GS, Chu MC, Wang JG, Sauer MV, Lobo RA. Elevated serum müllerian-inhibiting substance may be a marker for ovarian hyperstimulation syndrome in normal women undergoing in vitro fertilization. Fertil Steril. 2006;85:1541–3.CrossRefPubMed
19.
Kaya C, Pabuccu R, Satlroglu H. Serum antimullerian hormone concentrations on day 3 of the in vitro fertilization stimulation cycle are predictive of the fertilization, implantation, and pregnancy in polycystic ovary syndrome patients undergoing assisted reproduction. Fertil Steril. 2010;94:2202–7.CrossRefPubMed
20.
Catteau-Jonard S, Pigny P, Reyss AC, Decanter C, Poncelet E, Dewailly D. Changes in serum anti-Mu¨llerian hormone level during low-dose recombinant follicular-stimulating hormone therapy for anovulation in polycystic ovary syndrome. J Clin Endocrinol Metab. 2007;92:4138–43.CrossRefPubMed
21.
Mahran A, Abdelmeged A, El-Adawy AR, Eissa MK, Shaw RW, Amer SA. The predictive value of circulating anti-müllerian hormone in women with polycystic ovarian syndrome receiving clomiphene citrate: A prospective observational study. J Clin Endocrinol Metab. 2013;98:4170–5.CrossRefPubMed
22.
El-Halawaty S, Rizk A, Kamal M, Aboulhassan M, Al-Sawah H, Noah O, et al. Clinical significance of serum concentration of anti-Müllerian hormone in obese women with polycystic ovary syndrome. Reprod Biomed Online. 2007;15:495–9.CrossRefPubMed
23.
Durlinger AL, Gruijters MJ, Kramer P, Karels B, Kumar TR, Matzuk MM, et al. Anti-Mullerian hormone attenuates the effects of FSH on follicle development in the mouse ovary. Endocrinology. 2001;142:4891–9.PubMed
24.
Durlinger AL, Visser JA, Themmen AP. Regulation of ovarian function: the role of Anti-Mullerian hormone. Reproduction. 2002;124:601–9.CrossRefPubMed
25.
Durlinger AL, Kramer P, Karels B, de Jong FH, Uilenbroek JT, Grootegoed JA, et al. Control of primordial follicle recruitment by anti-Mullerian hormone in the mouse ovary. Endocrinology. 1999;140:5789–96.PubMed
26.
Grossman MP, Nakajima ST, Fallat ME, Siow Y. Mullerian-inhibiting substance inhibits cytochrome P450 aromatase activity in human granulosa lutein cell culture. Fertil Steril. 2008;89:1364–70.CrossRefPubMed
27.
Verit FF, Erel O, Kocyigit A. Association of increased total antioxidant capacity and anovulation in nonobese infertile patients with clomiphene citrate-resistant polycystic ovary syndrome. Fertil Steril. 2007;88:418–24.CrossRefPubMed
28.
Ahmed MI, Duleba AJ, El Shahat O, Ibrahim ME, Salem A. Naltrexone treatment in clomiphene resistant women with polycystic ovary syndrome. Hum Reprod. 2008;23:2564–9.CrossRefPubMed
Metadata
Title
Circulating anti-mullerian hormone as predictor of ovarian response to clomiphene citrate in women with polycystic ovary syndrome
Authors
Wenyan Xi
Yongkang Yang
Hui Mao
Xiuhua Zhao
Ming Liu
Shengyu Fu
Publication date
01-12-2016
Publisher
BioMed Central
Published in
Journal of Ovarian Research / Issue 1/2016
Electronic ISSN: 1757-2215
DOI
https://doi.org/10.1186/s13048-016-0214-2

Other articles of this Issue 1/2016

Journal of Ovarian Research 1/2016 Go to the issue

Research

GnRH antagonist rescue protocol combined with cabergoline versus cabergoline alone in the prevention of ovarian hyperstimulation syndrome: a randomized controlled trial

Research

Preoperative HE4, CA125 and ROMA in the differential diagnosis of benign and malignant adnexal masses

Research

Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer

Research

Histological analysis of arteriovenous anastomosis-like vessels established in the corpus luteum of cows during luteolysis

Research

The oviductal transcriptome is influenced by a local ovarian effect in the sow

Research

Supplementation of transport and freezing media with anti-apoptotic drugs improves ovarian cortex survival